Volume 27, Number 5—May 2021
Dispatch
Multisystem Inflammatory Syndrome in Children, Chile, May–August 2020
Table 1
Characteristic | Value |
---|---|
Median age, y (IQR) |
6.5 (2.0–10.5) |
Sex | |
M | 15 (57.7) |
F |
11 (42.3) |
Concurrent conditions | |
No | 20 (76.9) |
Obesity/overweight | 3 (11.5) |
Preterm | 1 (3.8) |
Acute lymphoblastic leukemia, Down syndrome |
1 (3.8) |
Nationality | |
Chilean | 19 (73.1) |
Venezuelan | 3 (11.5) |
Peruvian | 2 (7.7) |
Colombian | 1 (3.8) |
Haitian |
1 (3.8) |
Contact with SARS-CoV-2–positive patient |
10 (38.5) |
SARS-CoV-2 PCR results | |
Negative | 18 (69.2) |
Positive | 7 (26.9) |
Indeterminate |
1 (3.8) |
SARS-CoV-2 serologic assay results | |
Negative | 3 (16.7) |
IgM– IgG+ | 9 (50.0) |
IgM+ IgG+ |
6 (33.3) |
Positive PCR results for other co-infections | |
Rhinovirus | 1 (3.8) |
Rhinovirus and adenovirus |
1 (3.8) |
Signs and symptoms | |
Fever | 26 (100.0) |
Cough | 7 (26.9) |
Diarrhea | 16 (61.5) |
Vomiting | 12 (46.2) |
Abdominal pain | 17 (65.4) |
Conjunctivitis | 15 (57.7) |
Rash | 16 (61.5) |
Shock | 24 (92.3) |
Vasoplegic | 18 (75.0) |
Cardiogenic | 1 (4.2) |
Mixed | 5 (20.8) |
Myocarditis |
12 (46.2) |
Treatments | |
Invasive mechanical ventilation | 10 (38.5) |
Vasoactive drugs | 13 (50.0) |
Hyperimmune plasma | 1 (3.8) |
Corticoids | 23 (88.5) |
Intravenous immunoglobulin, doses | |
1 | 20 (76.9) |
2 | 2 (7.7) |
Tocilizumab | 3 (11.5) |
Infliximab | 1 (3.8) |
Acetylsalicylic acid | 19 (73.1) |
Low molecular weight heparin | 19 (73.1) |
Not used | 7 (26.9) |
Prophylaxis | 17 (65.4) |
Treatment | 2 (7.7) |
High-flow hemofiltration |
1 (3.8) |
Deaths | 0 |
Median intensive care unit admission, d (IQR) | 5 (2.0–7.0) |
Median hospitalization duration, d (IQR) |
10 (7.3–16.8) |
Echocardiogram results | |
Normal | 8 (30.8) |
LV systolic dysfunction† | 4 (15.4) |
Pericardial effusion | 3 (11.5) |
LV systolic dysfunction and pericardial effusion | 3 (11.5) |
Hyperdynamic | 1 (3.8) |
Mild LV diastolic dysfunction‡ | 2 (7.7) |
Coronary alterations§ | 5 (19.2) |
*Values are no. (%), except as indicated. IQR, interquartile range; LV, left ventricle; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2. †Defined as LV ejection <55%. ‡Defined as decreased E wave. §Defined as: Z-score 2–2.5, dilatation; Z-score 2.5–5, small aneurysm; Z-score 5–10, medium aneurysm; Z-score >10; giant aneurysm (14).
References
- Fu L, Wang B, Yuan T, Chen X, Ao Y, Fitzpatrick T, et al. Clinical characteristics of coronavirus disease 2019 (COVID-19) in China: A systematic review and meta-analysis. J Infect. 2020;80:656–65. DOIPubMedGoogle Scholar
- Ludvigsson JF. Systematic review of COVID-19 in children shows milder cases and a better prognosis than adults. Acta Paediatr. 2020;109:1088–95. DOIPubMedGoogle Scholar
- Riphagen S, Gomez X, Gonzalez-Martinez C, Wilkinson N, Theocharis P. Hyperinflammatory shock in children during COVID-19 pandemic. Lancet. 2020;395:1607–8. DOIPubMedGoogle Scholar
- Royal College of Paediatrics and Child Health. Guidance: paediatric multisystem inflammatory syndrome temporally associated with COVID-19. 2020 [cited 2020 Aug 30]. https://www.rcpch.ac.uk/sites/default/files/2020-05/COVID-19-Paediatric-multisystem-%20inflammatory%20syndrome-20200501.pdf
- Feldstein LR, Rose EB, Horwitz SM, Collins JP, Newhams MM, Son MBF, et al.; Overcoming COVID-19 Investigators; CDC COVID-19 Response Team. Multisystem inflammatory syndrome in U.S. children and adolescents. N Engl J Med. 2020;383:334–46. DOIPubMedGoogle Scholar
- Verdoni L, Mazza A, Gervasoni A, Martelli L, Ruggeri M, Ciuffreda M, et al. An outbreak of severe Kawasaki-like disease at the Italian epicentre of the SARS-CoV-2 epidemic: an observational cohort study. Lancet. 2020;395:1771–8. DOIPubMedGoogle Scholar
- Toubiana J, Poirault C, Corsia A, Bajolle F, Fourgeaud J, Angoulvant F, et al. Kawasaki-like multisystem inflammatory syndrome in children during the covid-19 pandemic in Paris, France: prospective observational study. BMJ. 2020;369:m2094. DOIPubMedGoogle Scholar
- Cabrero-Hernández M, García-Salido A, Leoz-Gordillo I, Alonso-Cadenas JA, Gochi-Valdovinos A, González Brabin A, et al. Severe SARS-CoV-2 infection in children with suspected acute abdomen: a case series from a tertiary hospital in Spain. Pediatr Infect Dis J. 2020;39:e195–8. DOIPubMedGoogle Scholar
- Whittaker E, Bamford A, Kenny J, Kaforou M, Jones CE, Shah P, et al.; PIMS-TS Study Group and EUCLIDS and PERFORM Consortia. Clinical characteristics of 58 children with a pediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2. JAMA. 2020;324:259–69. DOIPubMedGoogle Scholar
- Nakra NA, Blumberg DA, Herrera-Guerra A, Lakshminrusimha S. Multi-system inflammatory syndrome in children (MIS-C) following SARS-CoV-2 infection: review of clinical presentation, hypothetical pathogenesis, and proposed management. Children (Basel). 2020;7:69. DOIPubMedGoogle Scholar
- Prata-Barbosa A, Lima-Setta F, Santos GRD, Lanziotti VS, de Castro REV, de Souza DC, et al.; Brazilian Research Network in Pediatric Intensive Care, (BRnet-PIC). Pediatric patients with COVID-19 admitted to intensive care units in Brazil: a prospective multicenter study. J Pediatr (Rio J). 2020;96:582–92. DOIPubMedGoogle Scholar
- Torres JP, Izquierdo G, Acuña M, Pavez D, Reyes F, Fritis A, et al. Multisystem inflammatory syndrome in children (MIS-C): Report of the clinical and epidemiological characteristics of cases in Santiago de Chile during the SARS-CoV-2 pandemic. Int J Infect Dis. 2020;100:75–81. DOIPubMedGoogle Scholar
- Minesterio de Salud . Protocolo Síndrome Inflamatorio Multisistémico en niños, niñas y adolescentes con SARS-CoV-2. 2020 [cited 2021 March 4]. https://www.minsal.cl/wp-content/uploads/2020/07/Si%CC%81ndromeInflamatorio-Multisiste%CC%81mico.pdf
- McCrindle BW, Rowley AH, Newburger JW, Burns JC, Bolger AF, Gewitz M, et al.; American Heart Association Rheumatic Fever, Endocarditis, and Kawasaki Disease Committee of the Council on Cardiovascular Disease in the Young; Council on Cardiovascular and Stroke Nursing; Council on Cardiovascular Surgery and Anesthesia; and Council on Epidemiology and Prevention. Diagnosis, treatment, and long-term management of Kawasaki disease: a scientific statement for health professionals from the American Heart Association. Circulation. 2017;135:e927–99. DOIPubMedGoogle Scholar
- Radia T, Williams N, Agrawal P, Harman K, Weale J, Cook J, et al. Multi-system inflammatory syndrome in children & adolescents (MIS-C): a systematic review of clinical features and presentation. Paediatr Respir Rev. 2020 Aug 11 [Epub ahead of print].
Page created: March 18, 2021
Page updated: April 22, 2021
Page reviewed: April 22, 2021
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.